InMed Pharmaceuticals (FRA:MWG0) Net Income Including Noncontrolling Interests : €-5.63 Mil (TTM As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is InMed Pharmaceuticals Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

InMed Pharmaceuticals's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was €-1.59 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was €-5.63 Mil.

InMed Pharmaceuticals Net Income Including Noncontrolling Interests Historical Data

The historical data trend for InMed Pharmaceuticals's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals Net Income Including Noncontrolling Interests Chart

InMed Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Income Including Noncontrolling Interests

Get a 7-Day Free Trial

-8.94

-7.94

-8.47

-17.60

-7.34

InMed Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income Including Noncontrolling Interests	Get a 7-Day Free Trial															-1.87	-0.31	-2.38	-1.36	-1.59

InMed Pharmaceuticals Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.63 Mil.

InMed Pharmaceuticals Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

InMed Pharmaceuticals (FRA:MWG0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (FRA:MWG0) » Definitions » Net Income Including Noncontrolling Interests

Comparable Companies

Traded in Other Exchanges

INM:USA MWG0:Germany

Address

815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4

Website

https://www.inmedpharma.com

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals (FRA:MWG0) Headlines

No Headlines